RGDS peptide
(Synonyms: RGDS peptide; Fibronectin tetrapeptide) 目录号 : GC16385
RGDS peptide含有可介导细胞外基质蛋白与细胞整合素相互作用的Arg-Gly-Asp（RGD）序列，被广泛用于研究整合素功能。
Cas No.:91037-65-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
RGDS peptide contains the Arg-Gly-Asp (RGD) motif that mediates the interaction between extracellular matrix proteins and cell integrins and is widely used to probe integrin function[1]. RGDS peptide demonstrates significant antibacterial potential as an antibiotic adjuvant[2]. RGDS peptide covalently functionalized ND (NDCO-RGDS) can also be a tumor-targeting carrier of VEGF-siRNA[3].
In vitro, treatment of osteoblast-like cells with 0.2mM RGDS peptide for three days completely blocked apoptosis induced by staurosporine, the Ca2+·Pi ion pair, and sodium nitroprusside[4]. Following 500μg/mL RGDS peptide treatment for 2, 6, 16, and 24h, SK-MEL-110 cells internalized RGDS peptide in a time-dependent manner and exhibited marked anti-proliferative and pro-apoptotic effects independent of any extracellular anti-adhesive action[5].
In vivo, a single intraperitoneal injection of RGDS peptide 1h before lipopolysaccharide (LPS) challenge (1, 2.5, or 5mg/kg) dose-dependently suppressed the LPS-induced increases in neutrophil and macrophage counts, total protein content, TNF-α and macrophage inflammatory protein (MIP)-2 levels, and matrix metalloproteinase-9 activity in bronchoalveolar lavage fluid[6]. In Balb/c mice, a single intraperitoneal injection of RGDS peptide (5mg/kg) 30min before LPS (50μg/kg) and D-GalN (800mg/kg) markedly reduced hepatic injury and mortality[7].
References:
[1] Ortega-Velázquez R, Díez-Marqués ML, Ruiz-Torres MP, et al. Arg-Gly-Asp-Ser (RGDS) peptide stimulates transforming growth factor beta1 transcription and secretion through integrin activation. FASEB J. 2003;17(11):1529-1531.
[2] Feng Y, Xie W, Wan Z, et al. Harnessing RGDS peptides to regulate bacterial-host interfaces for targeted antimicrobial therapy. J Control Release. 2025;384:113922.
[3] Cui C , Wang Y , Zhao W , et al. RGDS covalently surfaced nanodiamond as a tumor targeting carrier of VEGF-siRNA: synthesis, characterization and bioassay. J Mater Chem B. 2015;3(48):9260-9268.
[4] Grigoriou V, Shapiro IM, Cavalcanti-Adam EA, et al. Apoptosis and survival of osteoblast-like cells are regulated by surface attachment. J Biol Chem. 2005;280(3):1733-1739.
[5] Aguzzi MS, Fortugno P, Giampietri C, et al. Intracellular targets of RGDS peptide in melanoma cells. Mol Cancer. 2010;9:84.
[6] Moon C, Han JR, Park HJ, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009;10(1):18.
[7] Yin X, Gong X, Jiang R, et al. Synthetic RGDS peptide attenuated lipopolysaccharide/D-galactosamine-induced fulminant hepatic failure in mice. J Gastroenterol Hepatol. 2014;29(6):1308-1315.
RGDS peptide含有可介导细胞外基质蛋白与细胞整合素相互作用的Arg-Gly-Asp（RGD）序列，被广泛用于研究整合素功能[1]。RGDS peptide作为抗生素佐剂亦表现出显著的抗菌潜力[2]。共价修饰的RGDS peptide功能化纳米金刚石（NDCO-RGDS）还可作为VEGF-siRNA的肿瘤靶向递送载体[3]。
在体外，0.2mM的RGDS peptide处理类成骨细胞3天，可完全阻断由星形孢菌素、Ca2+·Pi离子对和硝普钠诱导的细胞凋亡[4]。以500μg/mL的RGDS peptide处理SK-MEL-110细胞2、6、16和24小时后，RGDS peptide被细胞以时间依赖性方式摄取，并表现出显著的抗增殖和促凋亡效应，且该效应独立于其胞外抗黏附作用[5]。
在体内，于脂多糖（LPS）刺激前1小时单次腹腔注射1、2.5或5mg/kg的RGDS peptide，可剂量依赖性地抑制LPS诱导的支气管肺泡灌洗液中中性粒细胞和巨噬细胞数量、总蛋白含量、TNF-α和巨噬细胞炎症蛋白（MIP）-2水平以及基质金属蛋白酶-9活性的升高[6]。在Balb/c小鼠中，于LPS（50μg/kg）和D-GalN（800mg/kg）刺激前30分钟单次腹腔注射5mg/kg的RGDS peptide，可显著减轻肝损伤并降低死亡率[7]。
| Cell experiment [1]: | |
Cell lines | Osteoblast-like cells |
Preparation Method | To evaluate cell death, osteoblast-like cells were plated on experimental (RGDS peptide) and control (Arg-Gly-Glu-Ser (RGES)) substrates in 12- or 24-well plates at a density of 50,000/well or 25,000/well, respectively. After 3 days in culture in complete media, the osteoblasts were incubated overnight with sublethal doses of staurosporine (0.1 and 0.5μM), the Ca2+ (2.4 and 2.9mM) and Pi (3mM) ion pair, or sodium nitroprusside (0.5 and 0.1mM). |
Reaction Conditions | 0.2mM; 3 days |
Applications | Cells were grown on the RGDS peptide substrate and treated with 0.1 and 0.5μM staurosporine; no significant cell killing was observed. In contrast, staurosporine killed osteoblasts maintained on the RGES surface in a dose-dependent manner. Although 3mM Pi and 2.4mM Ca2+ did not kill osteoblasts grown on the RGDS peptide surface, there was a significant increase in cell death on the RGES surface. A further increase in cell death was apparent when osteoblasts were treated with 3mM Pi and 2.9mM Ca2+. Again, there was no significant increase in death among osteoblasts maintained on the RGDS peptide surface. The effect of the Nitric Oxide (NO) donor sodium nitroprusside on osteoblast apoptosis was similar to that of the Ca2+·Pi ion pair and staurosporine. At concentrations of 0.1 and 0.5mM, sodium nitroprusside killed 45 and 65% of osteoblasts cultured on the RGES surface, respectively. These concentrations of sodium nitroprusside failed to kill osteoblasts on the RGDS peptide surface. |
| Animal experiment [2]: | |
Animal models | Male BALB/C mice |
Preparation Method | Animals were anesthetized with a mixture of ketamine and xylazine (45mg/kg and 8mg/kg; i.p.; respectively). Test solution (30μl) containing lipopolysaccharide (LPS) (1.5mg/kg) was placed posterior to the throat and aspirated into the lungs. Control mice were administered sterile saline (0.9% NaCl). Animals were administered with RGDS peptide or Arg-Gly-Glu-Ser (RGES) peptide (1, 2.5, or 5mg/kg; i.p.) one hour before LPS treatment and sacrificed 4h post-LPS. Animals were also administered RGDS peptide or RGES peptide (5mg/kg; i.p.) once at different time points (1h before or 2h after LPS treatment) and sacrificed 24h post-LPS. |
Dosage form | 1, 2.5, or 5mg/kg; i.p. |
Applications | A pretreatment with RGDS peptide inhibited LPS-induced increases in neutrophil and macrophage numbers, total protein levels, and TNF-α and macrophage inflammatory protein (MIP)-2 levels, and matrix metalloproteinase-9 activity in bronchoalveolar lavage (BAL) fluid in a dose-dependent manner at 4 or 24h post-LPS treatment. RGDS peptide inhibited LPS-induced phosphorylation of focal adhesion kinase and mitogen-activated protein (MAP) kinases, including ERK, JNK, and p38 MAP kinase, in lung tissue. Importantly, the inhibition of the inflammatory responses and the kinase pathways was still evident when this peptide was administered 2h after LPS treatment. |
References: | |
| Cas No. | 91037-65-9 | SDF | |
| 别名 | RGDS peptide; Fibronectin tetrapeptide | ||
| 化学名 | (6R,12S,15R)-1,1,6-triamino-12-(carboxymethyl)-15-(hydroxymethyl)-7,10,13-trioxo-2,8,11,14-tetraazahexadec-1-en-16-oic acid | ||
| Canonical SMILES | O=C([C@@H](CCC/N=C(N)\N)N)NCC(N[C@H](C(N[C@@H](C(O)=O)CO)=O)CC(O)=O)=O | ||
| 分子式 | C15H27N7O8 | 分子量 | 433.42 |
| 溶解度 | ≥ 21.65mg/mL in Water | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3072 mL | 11.5362 mL | 23.0723 mL |
| 5 mM | 0.4614 mL | 2.3072 mL | 4.6145 mL |
| 10 mM | 0.2307 mL | 1.1536 mL | 2.3072 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet